A Brief Introduction to Antibody–Drug Conjugates for Toxicologic Pathologists

Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads

(2017) Joanna C. Masters et al.   INVESTIGATIONAL NEW DRUGS

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

(2017) Thomas H. Pillow et al.   MOLECULAR CANCER THERAPEUTICS

Structurally Defined αMHC-II Nanobody-Drug Conjugates: A Therapeutic and Imaging System for B-Cell Lymphoma

(2016) Tao Fang et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates

(2016) Carolin Sellmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity

(2016) M. L. Miller et al.   MOLECULAR CANCER THERAPEUTICS

Antibody Drug Conjugates: Nonclinical Safety Considerations

(2015) Mary Jane Masson Hinrichs et al.   AAPS Journal

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

(2014) W. Dokter et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

(2013) Kirsten Achilles Poon et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY